Arkolith/Insider Trading/NRXP/Form 4

Javitt Jonathan C

Chairman and Chief Scientist, Director, 10% OwnerNRX Pharmaceuticals, Inc. (NRXP) · full profile →Form 4 · filed Dec 18, 2024
Net Buying
Open-Market Buys
$47K
Open-Market Sells
$0
Net Open-Market Flow
$47K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 17, 2024Buy(P)40K$1.17$47K85K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-029694) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML